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A B S T R A C T
Objectives: To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma
analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the
Veneto region (Italy), where all drugs included in the recommended first line therapies were prescribed,
included integrase strand transfer inhibitors (InNSTI).
Methods: TDRMs were defined according to the Stanford HIV database algorithm.
Results: Subtype B was the most prevalent HIV clade (67.3%). A total of 92 patients (12.3%) were
expected to be resistant to one drug at least, most with a single class mutation (60/68–88.2% in subtype
B infected subjectsand 23/24–95.8% in non-B subjects) and affecting mainly NNRTIs. No significant
differences were observed between the prevalence rates of TDRMs involving one or more drugs, except
for the presence of E138A quite only in patients with B subtype and other NNRTI in subjects with non-B
infection.
The diagnosis of primary/recent infection was made in 73 patients (9.7%): they had almost only TDRMs
involving a single class. Resistance to InSTI was studied in 484 subjects (53 with primary-recent
infection), one patient had 143C in 2016, a total of thirteen 157Q mutations were detected (only one in
primary/recent infection).
Conclusions: Only one major InSTI-TDRM was identified but monitoring of TDRMs should continue in the
light of continuing presence of NNRTI-related mutation amongst newly diagnosed subjects, sometime
impacting also to modern NNRTI drugs recommended in first-line therapy.
© 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.
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More recent guidelines support the recommendation that all
patients with chronic HIV infection with detectable plasma HIV
viremia should start antiretroviral therapy (ART), regardless of CD4
+ cells count: the number of naive subjects who will be treated is
expected to increase in high-income countries and testing for
transmitted drug resistance mutations (TDRMs) is recommended
and cost-effective [1,2]. A definite and updated figure of TDRMs
burden is essential to build up therapeutic algorithms but the
prevalence rates differ because of the characteristics of patients
studied (infection by B or non-B subtype, recent or chronic disease)
and of availability of an efficient ART. Furthermore, there is an
underestimation of TDRMs when they are determined on plasma
samples and not on peripheral blood mononuclear cells (PBMCs):
less fit strains may be archived because wild-types had a better
replicative capacity in both acute and chronic patients [3,4].
The reported frequency of TDRMs ranged from 9.1% to 15% in
United States and it was below 10% in Europe [5–9]. The overall
prevalence in a European study (including Israel) on 4140 patients
who were newly diagnosed between 2008 and 2010 was 8.3%: it
was slightly higher in recently infected subjects (10.1%) than in
patients with an unknown date of infection (8.2%) [9]. An
individual-patient-level meta-analysis on 11,802 HIV-1 reverse
transcriptase sequences with or without protease retrieved from
42 studies (30 countries) showed a median study-level prevalence
of 9.4%: 5.6% of TDRMs were for nucleoside reverse transcriptase
inhibitors (NRTIs), 3.4% for non-nucleoside reverse transcriptase
inhibitors (NNRTIs), 1.5% for protease inhibitors (PIs), with a
subtype B prevalence of 67% [10].
With regard to primary/recent infections, TDRMs were detected
in 67 of 496 cases (13.5%) in USA: the most common major DRM
(drug resistant mutation) identified were associated with NNRTIs
resistance at 8.5% (42/496), with an increasing trend in the
proportion of patients with TDR (transmitted drug resistance) and
with TDR for NNRTIs throughout the study period (1996–2013)
[11]. In Europe a 9.4% prevalence was described in a Spanish cohort
for the time period 2009–2012 [12], comparable to that reported in
a French study (8.6%, years 2007–2012) [13].
In Italy we previously described a TDRMs rate of 11.3% in
patients with chronic subtype B infection (6.2% in subjects with
non-B subtype) and of 15.2% in subjects with primary infection
(8.7% in patients with non-B subtype) in the period 2010–2012. The
study started on 2004 and demonstrated a decline of PI resistance
and of combined resistance to two or three classes of drugs during
the study period [14]. The decrease of PI resistance was confirmed
by Montagna et al. [15], who analysed DRMs in a cohort of Italian
patients including both naive patients and subjects with virological
failure who made routine controls from 2003 to 2014. Integrase
strand transfer inhibitors (InSTI) were recently included in the first
line regimens because of their efficacy and excellent tolerability
[1,2]: InSTI resistance was not found in naive patients before the
drug was included in clinical practice and not even in 533 European
patients tested between 2008 and 2011 [16,17]. Of note, Frange
et al. [13] reported an integrase related mutation rate of 1.5% in a
cohort of 1318 French patients with primary infection diagnosed in
2007–2012. This data was not confirmed in the patients of the
Swiss cohort (0.1% in the study period 2008–2014) and in Spanish
patients with acute/recent infection diagnosed from May 2015 to
May 2016, possibly for the low number of subjects enrolled in these
two studies [18,19].
Here, we characterize the prevalence of TDRMs and the
circulation of non-B subtypes by plasma analysis of 750 patients
at the time of HIV diagnosis from January 1, 2013 to November 16,
2016 in the Veneto region (Italy), where all drugs included in the
recommended first line therapies were prescribed, included InSTI.2. Material and methods
2.1. Study design
Adult ART-naive-infected subjects were consecutively enrolled
in the study at the time of HIV infection diagnosis in seven
infectious disease units located in Veneto, Italy, between January 1,
2013 and November 16, 2016. Eligibility criteria included age
>18 years and antiretroviral drug-naive status according to a
personal interview and a review of the history of infection since the
first positive serological test, which was always performed at the
enrolling hospital.
The study was approved by the Ethical Committee for Clinical
Experimentation, Padua Province (Ethics Committee Protocol no.
2606-12P). The subjects gave informed consent for all procedures
and for the use of their blinded data for scientific evaluation and
publication. This study was conducted in accordance with the
Helsinki Declaration and local legislation.
Blood samples were processed within 6 h from collection to the
Laboratory of Virology at the University Hospital of Padova
(Padova, Italy) and stored until analysis.
Primary or recent HIV infection was defined by the presence of
any of the following: negative or indeterminate HIV antibodies by
enzyme-linked immunosorbent assay (ELISA) associated with a
positive plasma HIV RNA test; or an initially negative test for HIV
antibodies followed by positive serology within 18 months. The
absolute CD4+ cell count, percentage of CD4+ cells and HIV-RNA
plasma viral load were determined at sampling. HIV-RNA values
were not reported or used for statistical analyses because the
measurements during the 13 years were performed using the
current commercial methods, which changed over the course of
the study and exhibited a wide range of sensitivities, making the
values non-comparable. The results were compared with those of
the previous survey performed in 2004–2012 using the same
inclusion criteria [14].
2.2. HIV genotyping analysis
Genotyping was performed as previously described [3]. All
resistant strains were re-analysed twice to confirm the result. The
ViroSeq HIV-1 Genotyping System (Celera Diagnostics, Alameda,
CA) was used to genotype and to identify mutations.
2.3. Prediction of susceptibility and subtype analysis
The Stanford HIVdb drug resistance algorithm v.8.1.1 was
applied to assess the possible impact of TDRMs on the response to
therapy [20]. This algorithm assigns a drug-specific score to each
TDRM detected. The score obtained from the combination of all of
the TDRMs observed in a single viral strain is translated into one of
five levels of susceptibility: susceptible (S); potential low-level
resistance (PLR); low-level resistance (LR); intermediate resistance
(IR); and high-level resistance (HR). Reduced susceptibility was
scored when the Stanford system indicated the presence of
resistance with at least grade LR, allowing only clinically relevant
patterns to be considered. Subtyping was performed using
automated subtyping of HIV-1 genetic sequences for clinical and
surveillance purposes (REGA Institute Subtyping tool v.2.0 (http://
www.bioafrica.net/subtypetool/html/)) [21–23].
2.4. Statistical analysis
Categorical variables are expressed as percentages, and
quantitative variables are expressed as the mean and standard
deviation. The Chi-squared test and Fisher’s exact test were applied
to compare proportions, as appropriate. Student’s t-test was used
Table 1
Distribution by subtype, ethnicity and gender of the patients enrolled from January
1, 2013 to November 16, 2016 divided by subtype B and non-B infection. The results
were expressed as absolute numbers and percentages.
Enrollment periods 2013–2016
Total pts (n) 750
Pts with B subtype, n (%)a 505 (67.3%)
Italian Foreign
Male (n) 381 51
Female (n) 55 18
Total (n) 436 69
Pts with non-B subtype, n (%)b 245 (32.7%)
Italian Foreign
Male (n) 88 67
Female (n) 15 75
Total (n) 103 142
%c 42%
%d 19.1%
Pts: patients.
a Percentage of subjects with HIV-1 B subtype infection amongst the total
number of patients.
b Percentage of subjects with HIV-1 non-B subtype infection amongst the total
number of patients.
c Percentage of Italian subjects amongst the total number of patients with non-B
subtype.
d Percentage of Italian subjects with non-B subtype.
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MedCalc Statistical Software version 16.8.4 (MedCalc Software
bvba, Ostend, Belgium; https://www.medcalc.org; 2016). A p value
of <0.05 was considered statistically significant.
3. Results
3.1. Patients
A valid genotyping was obtained in plasma from 750 out of
762 patients (98.4%): their demographic characteristics and HIV
subtype are reported in Table 1.
The 12 patients with a result obtained from PBMC because of
failed plasma sequencing had a wild type virus.
Subtype B was the most prevalent HIV clade (505 patients,
67.3%): non-B subtype strains were found in 19.1% of Italian
patients (103 subjects) and in 67.3% of foreign-born subjects
(142 subjects) (p < 0.0001). Non-B strains included different
clades: subtype F was the most prevalent strain described in
Italian patients (27.2% versus 8.5% in foreigns, p = 0.0001). The
second most prevalent in Italian subjects was subtype CRF02_AG
(24.3%): this subtype was the first detected in foreign patients
(46.5%, p = 0.0004 respect to Italians) (Fig. 1).
Overall, the diagnosis of primary/recent infection was made in
73 patients (9.7%), a lower percentage respect to 2012–2013
(p = 0.02), due solely to the decrease in the cohort of patients with B
subtype infection (p = 0.0044). A detailed description of patients by
diagnosis and subtype is reported in Table 2.
In 2013–2016 study period subjects with chronic non-B
infection were younger and with a lower CD4+ cell count and
percentage respect to subjects with chronic subtype B infection
(p = 0.0027, p = 0.0356 and p = 0.0144 respectively).
3.2. Susceptibility prediction
A total of 92 patients (12.3%) were expected to be resistant to at
least one drug in the study period 2013–2016, most with a single
class mutation (60/68–88.2% in subtype B infected subjects and 23/
24–95.8% in non-B subjects) (Table 3). No significant differences
were observed between the prevalence rates of TDRMs involving
one or more drugs, except for higher rates of TDRMs that involved
NNRTI as single class in subjects with non-B infection (6.9% versusFig. 1. Distribution of non-B subtype clades identified in Italian patien3%, p = 0.0191) if E138A are not considered. The presence of
mutation E138A (mostly reported in B patients) was not included
in our previous DRM evaluation. This mutation was subsequently
reported to decrease susceptibility to rilpivirine and etravirine;
E138A increased, almost always detected without any other TDRM,
from 2.3% in 2004–2006 to 1.8% in 2007–2009, to 3.2% in 2010–
2012 and to 3.6% over the latter time period. In 2013–2016 E138A
was found in 26 B subtype (5.1%) and in only two (0.8%) non-B
infected subjects (Table 3).
Other nine out of 48 B subtype (19%, 1.8% of the cohort) and
5 out of twenty non B subtype patients (25%, 2% of the cohort) with
resistance to NNRTI-class, revealed TRDMs such as 101E, 138K,
181C and 190E, which compromise also new agents available for
first line therapy.
This data was confirmed also as relative weight amongst the
total resistant strains as single class (82.6% in patients with non-B
versus 68.3% with B subtype infection) and as global prevalence
including also combinations (83.3% versus 70.6%).ts and foreign subjects. Data are expressed as relative percentage.
Table 2
Age, CD4+ cell count and percentage amongst primary-recent and chronic HIV
infections of the patients enrolled from January 1, 2013 to November 16, 2016.
Patients are divided by subtype B and non-B subtype infection. Quantitative values
are expressed as mean and standard deviation.
2013–2016
B subtype 505
Diagnosis Primary Chronic
Pts n (%) 49 (9.7) 456 (90.3)
Age (years) 34.3 (11.2) 40.4 (11.3)
CD4+ cellsa 512 (263) 394 (271)
CD4+ cells % 27.1 (10.6) 20.8 (11.1)
Non-B subtype 245
Diagnosis Primary Chronic
Pts n (%) 24 (9.8) 221 (90.2)
Age (years) 33.4 (9.4) 37.6 (11.5)
CD4+ cellsa 562 (241) 347 (275)
CD4% 27.7 (8.5) 18.5 (12.1)
Pts: patients.
a Cells/mm3.
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with subtype B virus both as single class (28.3% versus 13%) and as
total frequency (33.8% versus 16.7%).
Overall, in 2013–2016 the prevalence of TDRMs increased in
subjects with non-B infection respect to 2010–2012: resistance
rates for NRTI, NNRTI and PI are comparable in the two study
periods. The detailed description is reported in Table 3. Amongst
non-B subtypes, NNRTI-related DRMs were found in eleven foreign
patients (only one in a case of acute-recent infection and one, in
combination with NRTI-DRM, in a chronic infected) and they were
mainly 103N or 181C. Only seven Italian patients with non-B
chronic infection had NNRTI-DRM, and they were mainly 103N or
181C as well.
Patients with primary-recent infection had almost only TDRMs
involving a single class in 2013–2016 study period: the frequency
was lower respect to the study interval 2010–2012 (Table 4).Table 3
Drug susceptibility prediction: single classes and combinations were reported and exp
transmitted drug resistance mutations.
NRTIa
n (%)
NNRTIb
n (%)
PIc
n (%)
NRTI + NNRTI
n (%)
N
n
B subtype
17 (3.3%) 15 (3%) 2 (0.4%) 4 (0.8%) 1
41d (8.1%)d
Non-B subtype
3 (1.2%) 17 (6.9%) 1 (0.4%) 1 (0.4%) 0
19d (7.7%)d
a NRTI: nucleoside Reverse transcriptase inhibitors.
b NNRTI: non-nucleoside reverse transcriptase inhibitors.
c PI: protease inhibitors.
d Including 138A.
Table 4
Susceptibility prediction in primary-recent infected patients of the patients enrolled from
percentage of patients harboring transmitted drug resistance mutations (TDRMs) out o
NRTI NNRTI PI NRTI + NNRTI NRTI 
B subtype
2013–16 1 1 0 1 0 
Non-B subtype
2013–16 0 1 0 0 0 
NRTI: nucleoside reverse transcriptase inhibitors.
NNRTI: non-nucleoside reverse transcriptase inhibitors.
PI: protease inhibitors.3.3. Susceptibility prediction to integrase strand transfer inhibitors
Sequences of integrase region were performed in 484 out of
750 subiects enrolled from 1 January 2013, according to availability
of plasma samples. No selection criteria was applied; 40 samples
were collected in 2013, 163 in 2014, 155 in 2015, 126 in 2016
(Tables 5a and 5b).
Amongst the 361 patients infected with B subtype, 43 (11.9%)
had a primary-recent infection and only one diagnosed in 2013 had
a 157Q mutation, a polymorphic accessory mutation. This subject
had no other TDRMs. Three hundred and eighteen patients with
chronic infection and B subtype demonstrated a wild type virus in
277 cases (87.7%); 32 (10.1%) had resistance to one or more of NRTI,
NNRTI or PI and 7 (2.2%) had 157Q (in two subjects associated to
NNRTI). Two 157Q were detected in 2013, 2 in 2014, one in
2015 and 2 in 2016. G163RK, non-polymorphic mutations in all
subtypes except subtype F, were recovered in two patients, G163K
in 2015 and G163R in 2016.
Amongst the 123 patients infected with non-B subtype, 10
(8.1%) had a primary-recent infection and none had InSTI related
TDRM. Ninety-nine chronic subjects with non-B subtypes
revealed a wild type (80.5%), 8 (6.5%) had resistance to one or
more of NRTI, NNRTI or PI and five had 157Q (in one subject
associated to NNRTI). One 157Q were detected in 2013, two in
2014, one in 2015 and one in 2016. One patient diagnosed in
2016 had 143C, a non-polymorphic major mutation; this subject
had no other TDRMs.
Of note, in the eight years period from 2009 to 2016, in the
seven infectious disease units of the Veneto area contributing to
this work, 83 experienced and InSTI failed patients were found to
have InSTI major DRMs by analysis in our laboratory: two in 2009,
four in 2010, eight in 2011, two in 2012, fourteen in 2013, eleven in
2014, sixteen in 2015 and twenty-six in 2016. About 4000 patients
were on treatment in these units, with viremic and failing subjects
able to transmit a resistant virus.ressed both as patient absolute number and as percentage of patients harboring
RTI + PI
 (%)
NNRTI + PI
n (%)
3 drug classes
n (%)
Total
n (%)
 (0.2%) 2 (0.4%) 1 (0.2%) 42/505 (8.3%)
68/505d (13.5%)d
 0 0 22/245 (9%)
24/245d (9.8%)d
 January 1, 2013 to November 16, 2016. Single drug classes, drug combinations and
f total patients were reported.
+ PI NNRTI + PI Three classes Total TDRMs/total patients
0 0 3/49 (6.1%)
0 0 1/24 (4.1%)
Table 5a
Prevalence of InSTI TDRMs amongst patients with B subtype HIV infection according to primary-recent or chronic infection. Quantitative values were expressed as mean and
standard deviation.
All patients Pts with primary-recent infection Pts with chronic infection
Number 361 43 318
Age (years) 38.8 (10.8) 32 (8.3) 39.7 (10.8)
CD4+ cell counta 401 (273) 501 (265) 386 (271)
CD4+ cells % 20.8 (10.9) 25.5 (9.3) 20.2 (10.9)
Plasma HIV RNAb 501,853 (1,594,266) 1,346,175 (2,783,875) 389,049 (1,328,951)
Pts with wild type virus, n (%) 316 (87.5) 39 (90.7) 277 (87.1)
Pts with NRTI TDRMs, n (%) 14 (3.9) 1 (2.3) 13 (4.1)
Pts with NNRTI TDRMs, n (%) 15 (4.1) 1 (2.3) 14 (4.4)
Pts with PI TDRMs, n (%) 1 (0.3) 0 1 (0.3)
Pts with NRTI + NNRTI TDRMs, n (%) 4 (1.1) 1 (2.3) 3 (0.9)
Pts with NRTI + PI TDRMs, n (%) 1 (0.3) 0 1 (0.3)
Pts with NRTI + NNRTI + PI TDRMs, n (%) 1 (0.3) 0 1 (0.3)
Pts with 157Q mutation, n (%) 8 (2 + NNRTI) (2.2) 1 (2.3) 7 (2 + NNRTI) (2.2)
Pts with 163R/K mutation, n (%) 2 (0.6) 0 2 (0.6)
Pts with 68IV mutation, n (%) 1 (0.3) 0 1 (0.3)
Pts with 97A mutation, n (%) 1 (0.3) 0 1 (0.3)
Pts with74IM mutation, n (%) 6 (1.7) 0 6 (1.9)
Pts with119R mutation, n (%) 2 (0.6) 0 2 (0.6)
Pts with 121 CFSY mutation, n (%) 1 (0.3) 0 1 (0.3)
Pts with 151I mutation, n (%) 1(0.3) 1 (2.3) 0
Pts with 163KRT mutation, n (%) 2(0.6) 0 2(0.6)
InSTI: integrase strand-transfer inhibitors.
NRTI: nucleoside reverse transcriptase inhibitors.
NNRTI: non-nucleoside reverse transcriptase inhibitors.
PI: protease inhibitors.
Pts: patients.
TDRMs: transmitted drug resistance mutations.
a Cells/mm3.
b Copies/ml.
Table 5b
Prevalence of InSTI TDRMs amongst patients with non-B subtype HIV infection according to primary-recent or chronic infection. Quantitative values are expressed as mean
and standard deviation.
All patients Pts with primary-recent infection Pts with chronic infection
Number 123 10 113
Age (years) 36.8 (11) 31.6 (3.3) 37.3 (11)
CD4+ cell counta 383 (286) 543 (197) 369 (285)
CD4+ cells % 19 (11.4) 23.3 (8.7) 18.3 (11.4)
Plasma HIV RNAb 718,784 (2,045,027) 1,056,657 (2,663,855) 684,130 (1,996,636)
Pts with wild type virus, n (%) 109 (88.6) 10 (100) 99 (87.6)
Pts with NRTI TDRMs, n (%) 2 (1.6) 0 2 (1.8)
Pts with NNRTI TDRMs, n (%) 6 (4.9) 0 6 (5.3)
Pts with PI TDRMs, n (%) 1 (0.8) 0 1 (0.9)
Pts with NRTI + NNRTI TDRMs, n (%) 0 0 0
Pts with NRTI + PI TDRMs, n (%) 0 0 0
Pts with NRTI + NNRTI + PI TDRMs, n (%) 0 0 0
Pts with 157Q mutation, n (%) 5 (1 + NNRTI) (4.1) 0 5 (1 + NNRTI) (4.4)
Pts with 143C mutation, n (%) 1 (0.8) 1 (0.9)
Pts with 68IV mutation, n (%) 1 (0.8) 0 1 (0.9)
Pts with 97A mutation, n (%) 20 (1 + PI) (16.3) 0 20 (1 + PI) (17.7)
Pts with 74IM mutation, n (%) 20 (1 + PI) (16.3) 1 (10) 19 (1 + PI) (16.8)
Pts with 119R mutation, n (%) 2 (1.6) 1 (10) 1 (0.9)
Pts with 121 CFSY mutation, n (%) 0 0 0
Pts with 151I mutation, n (%) 0 0 0
Pts with 260I mutation, n (%) 1 (0.8) 0 1 (0.9)
InSTI: integrase strand-transfer inhibitors.
NRTI: nucleoside reverse transcriptase inhibitors.
NNRTI: non-nucleoside reverse transcriptase inhibitors.
PI: protease inhibitors.
Pts: patients.
TDRMs: transmitted drug resistance mutations.
a Cells/mm3.
b Copies/ml.
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This study described TDRMs identified in ART naive subjects
during the last four years in a well identified geographical setting
with a known and previously analysed HIV patients cohort (years
2004–2012) [14]. This characteristic allowed to show a timely
picture and to point out how TDRMs modified with the progressive
increase of the InSTI inclusion in the ART regimens.
Our data on higher frequency of TDRMs in patients with B
subtype respect to those with non-B infection when E138A is
included in the analysis are in agreement with those reported by
Descamps et al. [24] in a 2010–2011 survey (11.9% versus 5.1%
respectively). Conversely, we reported a comparable rate of TDRMs
in the two cohort of our patients (8.3% and 9% respectively) when
E138A is not evaluated, because of the higher frequency of
detection of E138A in patients with subtype B infection.
The decrease of TDRMs identified in patients with primary
infection was reported both in subjects with non-B and B infection
but the number of patients with primary infection was signifi-
cantly lower respect to 2010–2012 only in the cohort of individuals
infected with subtype B. There is a great variability in TDRMs
frequency described in patients diagnosed with acute disease and
different inclusion criteria may play a role [12,25,26]. Resistance
mutations that affect replication may revert and outgrowth of wild
type virus, which is more replication competent, may occur in
patients infected for less than 6 months [27]. Furthermore,
transmitted viruses that contain mutations may be archived in
lymphocyte reservoirs very early during acute HIV infection [4].
Mutations associated with NNRTI alone were observed
frequently, 3% insubtype B and 6.9% in non-B subtype virus
infection. Of note, these frequencies raised up to 8.1% and 7.7%
respectively when polymorphic mutation E138A is included and to
9.5% and to 8.2 when all NNRTI combinations are considered.
E138A mutation (always as isolated mutation) was detected mostly
in patients with subtype B, who are the 67.3% of our study
population, with a prevalence comparable to that described by
Alvarez et al. [28] in a Spanish cohort of naive patients recruited in
the period 2007–2011: however in this study no data on patient’s
HIV genotype was included. Analysis by genotype was available in a
French study including patients tested from 2008 to 2011: only half
of patients had a B subtype virus and E138A was found in 2% of
them, versus 4.1% in non-B subtype viruses [29]. It was not possible
to speculate on the origin of the acquisition of resistant strains in
non-B subtypes; our analysis was performed at the time of HIV
diagnosis, but most TDRMs in non-B subtypes were found in
subjects with chronic infection and were NNRTI-related DRMs.
Ripilvirine became more widely used in clinical practice as third
drug alternative to InSti in selected clinical conditions [2]: of note,
a small proportion of subjects with NNRTI-TDRM was predicted to
fail also the only NNRTI-recommended first line regimen, then
resistance testing at beginning is mandatory.
Amongst non-B subtypes, CRF02_AG was the most prevalent
strain detected in foreign patients and the second most frequent
and in Italians this spread had clinical implications, because of
possible under-quantification of plasma HIV RNA value with
commercial tests [30–32].
Interestingly, the non-B subtype pattern is different in Italians
and foreigns, suggesting a compartmentalised transmission in
newly HIV diagnosed Italian patients. Subtype F was identified in a
growing proportion of subjects with non-B virus [14,33]: Pernas
et al. [34] reported that subtype F was an independent predictor of
poor virological response after 24 weeks of ART in patients at the
first HIV diagnosis from 2009 to 2013 (the majority being Spanish).
No signature InSTI-resistant variants were circulating in
Europe before the introduction of InSTIs and more recently
polymorphisms and substitutions conferring low-level resistanceto raltegravir and elvitegravir were found in acute-recent infected
patients [16,19]. Prevalence of InSTI transmitted drug resistance
may increase with the increasing use of InSTIs, but it was recently
reported that their prevalence was stable although InSTIs were
increasingly used in the Swiss cohort [18], and this is in contrast
to the introduction of previous drug classes where more
treatment failures with resistant strains occurred and TDR was
observed more rapidly. Likewise, the wide availability of InSTIs
from at least seven years in our hospitals allowed to determine
the conditions to select resistant strains and to transmit those
strains to the newly infected or to superinfect HIV-patients.
Despite the detection of a substantial number of resistant strains
in the treated population, we demonstrate on a considerable
population sample recruited from 2013 until very recent times,
including 11% of recently infected, the almost total absence of
major InSTI-TDRM (one out of 484 subjects) in both chronic and
primary-recent infected with B and non-B subtypes in our region.
Few polymorphic accessory variants were detected, quite always
as isolated mutations. Of note, we identified 263K mutation in a
patient with subtype B infection: it was recently detected only by
ultradeep sequencing in two out of 92 naive patients newly
diagnosed in 2013–2015 [35]. Monitoring of TDRMs should
continue in the light of persisting presence of NNRTI-related
mutations amongst newly diagnosed subjects, sometime impact-
ing also to modern NNRTI drugs recommended in first-line
therapy; further a surveillance of InSTI-TDRMs should be
performed given the role of these drugs in recent guidelines.
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